Polyphenols as mitochondria-targeted anticancer drugs

Area of Science:

• Mitochondrial biology and cancer therapeutics.

Background:

• Mitochondria are key cellular energy producers and sites of signal transduction, making them targets for cancer drugs.
• Mitochondria-targeted anticancer drugs (mitocans) act through various mechanisms, including inhibition of enzymes, disruption of protein interactions, and interference with cellular respiration.
• Plant-derived polyphenols possess diverse biological activities, including those relevant to mitocan action.

Purpose of the Study:

• To review the classification of mitocans based on their molecular modes of action.
• To highlight the potential of plant-derived polyphenols and their derivatives as novel mitocans.
• To discuss examples of successful development from natural compounds to clinical drug candidates.

Main Methods:

• Classification of mitocans based on a 2013 review by Neuzil et al.
• Identification of polyphenols with known anticancer properties and mitocan-like activities.
• Review of existing clinical trial data for relevant compounds.

Main Results:

• Mitocans are categorized into eight distinct classes based on their molecular targets within mitochondria.
• Polyphenols exhibit pleiotropic effects, aligning with several mitocan action modes.
• Gossypol derivatives (e.g., ABT-737, ABT-263) and modified phenolic compounds (e.g., quercetin, resveratrol) show efficacy in inducing cancer cell death.

Conclusions:

• Plant-derived polyphenols represent a promising source for developing novel and effective mitocans.
• Targeting mitochondrial pathways offers a viable strategy for cancer therapy.
• Further research and clinical trials are warranted for these promising compounds.